Board Member
Orthofix Medical Inc. (OFIX)Equibles does not estimate personal net worth.
Get an email with a short summary when Orthofix Medical Inc. publishes a filing, an earnings call transcript or a press release.
Get OFIX alertsMassimo Calafiore is recorded as Board Member at Orthofix Medical Inc. (OFIX) since January 1, 2024 and CEO at Orthofix Medical Inc. (OFIX). The newest filing on record that lists Massimo Calafiore as Board Member at Orthofix Medical Inc. (OFIX) is dated April 29, 2026. The newest filing on record that lists Massimo Calafiore as CEO at Orthofix Medical Inc. (OFIX) is dated April 30, 2025. Orthofix Medical Inc. reported in an 8-K filed January 9, 2024 that Massimo Calafiore was appointed Director, effective January 8, 2024. Orthofix Medical Inc. reported in an 8-K filed January 9, 2024 that Massimo Calafiore was appointed President and Chief Executive Officer, effective January 8, 2024. Orthofix Medical Inc. reported in an 8-K filed December 1, 2023 that Massimo Calafiore was appointed President and Chief Executive Officer. Massimo Calafiore has spoken on 11 earnings calls and 4 other investor events across 1 company, most recently for Orthofix Medical Inc. on August 12, 2026. Orthofix Medical Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Orthofix Medical Inc. includes Catherine M. Burzik (CEO and Chairman), Jon Serbousek (CEO and Chairman), Catherine Burzik (Chairman) and 7 others.
“the Board expanded the size of the Board as of January 8, 2024 from eleven to twelve directors, and appointed Mr. Calafiore to fill the newly created seat.”
“On January 8, 2024, the Company’s Board of Directors (the “Board”) appointed Massimo Calafiore as the Company’s President and Chief Executive Officer, and Mr. Calafiore began service on such date.”
“You know, before I let Julie answer the question, I want to step back and remind everybody, you know, the progress that we made in just two years. You know, since the beginning, we more than doubled our EBITDA since the inception.”
“Our second quarter results provide further evidence that the operational actions we have taken over the past year are showing up more clearly in the business.”
“So when we joined in 2024, we found a company with a pretty solid portfolio across the vertical where we compete, but with a lot of challenges on the operating model.”
“First quarter results reflect steady execution, improving stability and sharper strategic focus.”
“My name is Matt Blackman, the newest member of the TD Cowan MedTech Research Team.”
2024-01-01–present
Last confirmed April 29, 2026
Start not stated–present
Last confirmed April 30, 2025
Medical Devices · Healthcare
CEO, Board Member
2024-01-01–present
